NEW YORK, March 16 - German Genomics company GPC Biotech said Friday its 2000 revenues more than doubled to 10.9 million euros ($9.8 million), compared with 4.3 million euros in 1999, as the company forged several new research alliances with companies such as Aventis, Boehringer Ingelheim, Altana, and Karo Bio.

In addition to performing contract genomics and proteomics research, the company is also developing an in-house pipeline for drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.